微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 39.14% | 10.34% | 2.37% | 93/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 38.23% | 7.91% | 2.27% | 97/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 37.39% | 5.84% | 7.88% | 98/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 34.66% | -11.54% | -2.3% | 111/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 35.47% | -11.42% | 0.11% | 108/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 35.43% | -10.88% | 0.3% | 108/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 35.33% | -8.84% | -9.82% | 107/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 39.17% | 51.94% | -2.18% | 106/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 40.05% | 50.51% | 0.72% | 106/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 39.76% | 41.5% | 2.6% | 104/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 38.75% | 15.65% | 50.3% | 103/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 25.78% | -29.66% | -3.1% | 131/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 26.61% | -29.92% | -5.31% | 123/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 28.1% | -28.68% | -16.14% | 124/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.51% | -19.94% | -8.58% | 105/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 36.65% | -29.04% | -3.46% | 117/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 37.96% | -27.96% | -3.64% | 99/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 39.4% | -23.16% | -5.86% | 102/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 41.85% | -19.5% | -18.97% | 81/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 51.65% | -7.94% | -2% | 77/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 52.7% | -3.08% | 2.79% | 65/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 51.27% | -1.49% | -1.38% | 69/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 51.99% | 7.02% | -7.34% | 60/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 56.11% | 39.34% | 3.18% | 68/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 54.38% | 50.92% | 4.48% | 56/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 52.04% | 66.5% | 7.13% | 59/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 48.58% | 45.22% | 20.65% | 61/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 40.27% | 6.51% | 11.75% | 95/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 36.03% | -9.65% | 15.27% | 81/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.26% | -21.62% | -6.57% | 89/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 33.45% | -12.68% | -11.5% | 81/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.8% | 0.94% | -5.21% | 82/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 39.88% | 2% | 0.01% | 59/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.88% | 2% | 6.48% | 63/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 37.45% | 13.77% | -2.25% | 74/159 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-03-31 | 38.31% | 2% | 16.38% | 44/159 | 43.5% | 贝达药业 | 95.58% | 行业排名> |
| 2015-12-31 | 32.92% | 16.01% | 16.01% | 75/159 | 45.97% | 贝达药业 | 95.89% | 行业排名> |